Hence, higher endostatin levels in patients without lymph node metastasis may be due to the endostatin effect on lymph expansion, which can inhibit lymph angiogenesis by down-regulating VEGF-C expression in tumor cells (24). The gene discussed is VEGFC; the disease is metastatic malignant neoplasm in the lymph nodes.